Vactech Appoints Dr. Tero Välimaa as New Chief Executive Officer.
Experienced Leader Brings Over 25 Years of Pharmaceutical and Medical Device Expertise to Vactech
The Company
"We develop and license vaccines and novel technologies for vaccines and diagnostics."
Our flagship project is a patented enterovirus based preventive Type 1 Diabetes (T1D) vaccine, similar to the widely used enterovirus vaccine against polio. Our other projects include new treatments and diagnostics for Celiac Disease, all covered by patents.
Type 1 Diabetes (T1D)
Type 1 Diabetes is one of the most common chronic, life-long diseases globally, and it is most often diagnosed in children, adolescents and young adults.
Preventive Type 1 Diabetes vaccine
Vactech is developing a vaccine for the prevention of Type 1 Diabetes.
Other immune-mediated diseases and technology
In addition to Type 1 Diabetes Vactech is developing applications in the fields of Diagnostics, Asthma & Allergy, Celiac Disease and Virus Like Particles.